GB1399539A — Tricyclic ureas processes for preparing them and pharma ceutical compositions containing them

USPTO Abstract

1399539 Dibenzazepine and phenothiazine derivatives SCIENCE UNION ET CIE SOC FRANCAISE DE RECHERCHE MEDICALE 5 Nov 1973 [3 Nov 1972] 50697/72 Heading C2C Novel compounds of Formula I in which A is -S-, -CH 2 -CH 2 - or -CH=CH-, each of R and R 1 is H, halogen, CF 3 , OCF 3 , C 1-6 alkoxy or C 1-6 alkylthio, R 4 is H, C 1-6 alkyl or substituted C 1-6 alkyl, R 2 is H, C 1-6 alkyl, substituted C 1-6 alkyl, C 2-10 alkenyl, C 2-6 alkynyl, phenyl-C 1-6 alkyl or (substituted phenyl)-C 1-6 alkyl, R 3 is C 1-6 alkyl, substituted C 1-6 alkyl, C 2-10 alkenyl, C 2-6 alkynyl phenyl- C 1-6 alkyl or (substituted phenyl)-C 1-6 alkyl or -NR 2 R 3 represents a 3- to 7-membered heterocyclic ring, and acid addition salts thereof, are prepared by reaeting a compound of Formula II in which X is Cl, Br or I or a group of formula -OCOR 5 , where R 5 is an alkoxy or alkyl radical or a radical of the Formula III with a compound of formula The compounds I in which R 2 is H may also be prepared by debenzylation of compounds I in which R 2 is benzyl or substituted benzyl. 5 - Ethoxycarbonyl - 3,7 - dichloro - 10,11 - dihydro - 5H - dibenz[b,f]azepine is prepared by reacting 3,7 - dichloro - 10,11 - dihydro - dibenz- [b,f]azepine with ethyl chloroformate. Pharmaceutical compositions having antiarrhythmic activity, for oral, parenteral, sublingual or rectal administration, comprise a compound I or a pharmaceutically acceptable acid addition salt thereof, together with a pharmaceutical carrier.